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osting by EAbstract A series of 5,6-bis(4-substitutedphenyl)-2H(3)-pyridazinones 2a–f have been synthesized
from the condensation of the corresponding benzil monohydrazones 1 either with ethyl cyanoace-
tate or diethyl malonate in ethanol. The synthesized pyridazinones were converted to the corre-
sponding 3-chloro derivatives 3a–f by the action of phosphoryl chloride. Reaction of the latter
halogenated pyridazines with various aromatic amines led to the formation of new 3-aminoaryl
pyridazines (4) in moderate yield. The structures of all new compounds 2b,c,e,f, 3b–e, 4 were fully
identiﬁed by the analysis of their 1H and 13C NMR and mass spectra. Some of these synthetic het-
erocyclic compounds were screened for their antimicrobial activities but they were almost negative.
ª 2009 King Saud University. All rights reserved.1. Introduction
In recent years, a great deal of work have been directed to the
organic synthesis of pyridazines. These nitrogen heterocyclic
compounds are of biological importance and therefore, design
and strategy for their synthesis is important. Pyridazines, and
in particular 3-pyridazinone derivatives, are known for a wide
range of biological activities. They posses antibacterial.M.A. AL-Hazimi).
ity. All rights reserved. Peer-
d University.
lsevier(Ibrahim et al., 1993; Seada et al., 1989; Kamal El-Dean and
Radwan, 1998), antifungal (Kamal El-Dean and Radwan,
1998; Ralph et al., 1988) and insecticidal (Numata et al.,
1988) activities. Further, a number of these nitrogen heterocy-
cles showed a promising pharmacological activities such as 6-
phenyl 2H(3)-pyridazinones as antihypertensive (Demirayak
et al., 2004; Wermuth et al., 1989; Curran and Adma Ross,
1944; McEvoy and Allen, 1974), cardiotonic (Cignarella
et al., 1986; Howson et al., 1988; Okushimo et al., 1987), antin-
ociceptive (Piaz et al., 2003; Frank and Heinish, 1992) agents
as well as coagulants (Cignarella et al., 1986; Sotelo et al.,
2002; Coelho et al., 2004; Sircar et al., 1985).
Also, many of N-alkylated 3-pyridazinones have been
found to be inhibitors of Interleukin-1b production (Matsuda
et al., 2001a,b). In view of the above mentioned biological and
pharmacological importance of the title compounds, and due
to our increased activity involved in the synthesis of a variety
of nitrogen-containing heterocycles during the past few years
(El-Baih et al., 2000; El-Baih, 2003; El-Baih et al., 2006a,b;
102 H.S. Alonazy et al.El-Shehry et al., 2008), we report herein the synthesis of a ser-
ies of novel 5,6-bis(4-substitutedphenyl)-3-(2H)-pyridazinones
(2a–f), the corresponding chloro derivatives (3a–e), and cou-
pling products of the latter compounds with some aromatic
amines (4). All synthesized compounds have been structurally
elucidated on the basis of spectroscopic means.
2. Experimental
Starting materials were obtained from commercial suppliers
and used without further puriﬁcation. Melting points are deter-
mined on an electrothermal’s IA9000 series digital capillary
melting point apparatus and are uncorrected. IR spectra were
run (KBr discs) on Perkin Elmer FT spectrophotometer 1000.
1H and 13C NMR spectra were recorded on a JEOL ECP 400
NMR spectrometer operating at 400 MHz in DMSO-d6 unless
otherwise stated with TMS as internal standard. DEPT and
HETCOR experiments were recorded on 500 MHz instrument
(Brucker, J.F.B. 288) at King Saud University (Pharmacy Re-
search Centre). Chemical shifts are given in d ppm and coupling
constants (J) are given in Hz. Electron impact (EI) MS spectra
were carried on Shimadzu GCMSQP5050A spectrometer, DB-
1 glass column 30 m, 0.25 mm, ionization energy 70 eV, at
Chemistry Department, College of Science, King Saud Univer-
sity. The reactions were monitored by TLC.
2.1. Benzil monohydrazones (1a–c)
A mixture of benzil derivative (0.075 mol) and hydrazine hy-
drate 99%(0.075)washeated in 50 ml ethanol (96%)onoil bath,
and the reaction wasmonitored by TLC. After reaction comple-
tionwhich takes 9 h, 29 h and 11 h, respectively, themixture was
kept to cool overnight at 0–5 C. The precipitate was ﬁltered,
washed by ethanol and recrystallised from ethanol.
2.1.1. 2-Hydrazono-1,2-diphenylethanone (1a)
White powder, m.p. 154–156 C, lit. (Druey and Schemidt,
1957) 151 C, yield 79%; IR (cm1): 1626 (C‚O) , 1441.2
(C‚N); MS: m/z 212 [M+]; 1H NMR(CDCl3): d 6.30 (2H,
s, NH2), 7.35 (2H, d, J= 8.08 Hz, H-2
0,60), 7.46 (3H, t,
J= 7.32 Hz, H-30,40,50), 7.53 (3H, t, J= 7.36 Hz, H-
300,400,500), 7.96 (2H, dd, J= 6.60 Hz, J= 4.40 Hz, H-200,600);
13C NMR(CDCl3): d 145.5 (C‚N), 191.9 (C‚O), 127.80
(C-30,50), 129.00 (C-300,500), 129.30 (C-20,40,60), 130.20 (C-
200,600), 131.60 (C-400), 129.80 (C-10), 138.20 (C-100).
2.1.2. 1,2-Bis(4-bromophenyl)-2-hydrazonoethanone (Ib)
White needles, m.p. 185–186 C, yield 63%; IR (cm1): 1622.6
(C‚O), 1348.7 (C‚N); MS: m/z 384 [M+4] (C14H10-
N2O
81,81Br2) (25.71%), 382 [M+2] (C14H10N2O
79,79Br2)
(52.16%), 380 [M+] (C14H10N2OBr2) (29.03%);
1H NMR
(DMSO-d6): d 8.23 (2H, s, NH2), 6.69 (2H, d, J= 8.08 Hz, H-
30,50), 7.06 (2H, d, J= 8.80 Hz, H-20,60),7.14 (2H, d, J=
8.80 Hz, H-300,500), 7.31 (2H, dd, J= 8.80, 2.20 Hz, H-200,600);
13C NMR (DMSO-d6): d 146.1 (C‚N), 190.19 (C‚O), 123.37
(C-40), 126.25 (C-400), 127.72 (C-10), 130.32 (C-20,60), 130.63 (C-
30,50), 131.07 (C-200,600), 132.07 (C-100), 132.00 (C-300,500).
2.1.3. 1,2-Bis(4-methoxyphenyl)-2-hydrazonoethanone (Ic)
Yellowish needles, m.p. 132–134 C, yield 65%; IR (cm1):
1628 (C‚O), 1412.3 (C‚N); MS: m/z 284 [M+]
(C16H16N2O3) (42.88%), 149 [M
+C8H7O2] (100%), 135[M+C8H9N2O] (51.36%); 1H NMR(CDCl3): d 6.18 (2H, s,
NH), 3.83, 3.85 (each 3H, s, 2X-OCH3), 6.92 (2H, dd,
J= 8.80, 1.48 Hz, H-30,50), 7.02 (2H, dd, J= 8.80, 2.20 Hz,
H-300,500), 7.29 (2H, dd, J= 6.60, 2.20 Hz, H-20,60), 8.00 (2H,
dd, J= 8.80, 6.60 Hz, H-200,600); 13C NMR(CDCl3): d 145.9
(C‚N), 190.57 (C‚O), 55.40 (OCH3), 55.00 (OCH3), 113.20
(C-30,50), 114.70 (C-300,500), 122.00 (C-10), 130.40 (C-20,60),
130.60 (C-100), 132.70 (C-200,600), 160.10 (C-400), 162.60 (C-400).
2.2. General procedure for the preparation of pyridazinones
(2a–f)
A solution of sodium metal (0.1 mol) in absolute alcohol
(150 ml) was prepared. This solution was gradually added
to a solution of equimolar amounts of 0.1 mole of the appro-
priate hydrazone 1a–c and 0.1 mole of ethyl cyanoacetate or
diethyl malonate in absolute ethanol (150 ml). Then, the mix-
ture was reﬂuxed for some hours as judged by TLC. The time
was 6, 16, 16 h for 2a–c and 11, 17, 18 h for 2d–f, respectively.
The reaction mixture was then evaporated under reduced
pressure until dryness, then, ice was added to the residue acid-
iﬁed by HCl solution (2 N). The formed precipitate was ﬁl-
tered, washed with distilled water and recrystallized from
ethanol for 2a–c and from benzene 2d–f, to give the required
pyridazinone 2 with moderate yield. NMR data of 2a–f were
reported in Table 1.
2.2.1. 3-Oxo-5,6-diphenyl-2,3-diydropyridazine-4-
carbonitrile(2a)
White powder, m.p. 272–274 C, lit. (Schemidt and Druey,
1954) 272–273 C, yield 50%; IR (cm1): 1660.6 (C‚O),
2229.4 (CN); MS: m/z 273 [M+] (C17H11N3O) (100%), 274
[M++1] (C17H12N3O) (15.56%); NMR (dH, dC): Table 1.
2.2.2. 5,6-Bis(4-bromophenyl)-3-oxo-2,3-diydropyridazine-4-
carbonitrile (2b)
White powder, m.p. 275–276 C, yield 49%; IR (cm1): 1700.6
(C‚O), 2228.4 (CN); MS: m/z 429 [M+] (C17H9N3OBr2)
(40.55%), 431 [M++2] (C17H11N3OBr2) (71.89%), 433
[M++4] (C17H12N3OBr2) (38.77%); NMR (dH, dC): Table 1.
2.2.3. 5,6-Bis(4-methoxyphenyl)-3-oxo-2,3-diydropyridazine-4-
carbonitrile (2c)
Yellowish needles, m.p. 235–236 C, yield 59%; IR (cm1):
1661 (C‚O), 2227.13 (CN); MS: m/z 333 [M+] (C19H15-
N3O3) (100%), 318 [M
+CH3] (9.29%), 302 [M+OCH3]
(5.37%); NMR (dH, dC): Table 1.
2.2.4. Ethyl 3-oxo-5,6-diphenyl-2,3-diydropyridazine-4-
carboxylate (2d)
White powder, m.p. 224–226 C, lit. (Druey and Schemidt,
1957) 219–220 C, yield 51%; IR (cm1): 1647.11 (C‚O),
1737.14 (COO); MS: m/z 320 [M+] (C19H16N2O3) (62.70%),
291 [M+C2H5] (2.77%), 275 [M+C2H5O] (43.85%);
NMR (dH, dC): Table 1.
2.2.5. Ethyl 5,6-bis(4-bromophenyl)-3-oxo-2,3-diydropyri-
dazine-4-carboxylate (2e)
White powder, m.p. 248–250 C, yield 61%; IR (cm1): 1645
(C‚O), 1743 (COO); MS: m/z 476 [M+] (C19H14N2O3
79,79Br2)
(42.83%), 478 [M++2] (C19H16N2O3
79,81Br2) (100%), 480
[M++4] (C19H14N2O3
81,81Br2) (44.80%);NMR(dH, dC): Table 1.
Table 1 NMR Spectral data (CDCl3, DMSO-d6) of chloro-pyridazines 2a–f.
Compound
No.
Chemical shifts (dH) in ppm Chemical shifts (dC) in ppm
2a* 14.11 (1H, s, NH), 7.10 (2H, d, J= 8.08 Hz, H-30,50), 7.30
(5H, m, H-300,40,50,20,60), 7.44 (3H, m, H-200,400,600)
158.0 (C‚O), 114.42 (CN), 113.98 (C-4), 128.44 (2C), 128.96
(2C), 129.11 (C-40), 129.32 (2C), 129.62 (2C), 130.44 (C-400),
133.86 (C-10), 135.29 (C-100), 146.45 (C-5), 152.38 (C-6)
2b* 33.03 (1H, s, NH),7.05 (2H, d, J= 8.08 Hz, H-30,50), 7.21 (2H,
d, J= 8.80 Hz, H-20,60), 7.43 (2H, d, J= 8.80 Hz, H-300,500),
7.61 (2H, d, J= 8.04 Hz, H-200,600)
162.74 (C‚O), 116.13 (CN), 121.79 (C-40), 123.53 (C-400),
131.38 (C-20,60), 131.65 (C-200,30,50,600), 132.10 (2C), 134.03
(C-4), 136.07 (C-100), 143.85 (C-10); 145.50 (C-5), 154.00 (C-6)
2c* 13.96 (2H, s, NH), 3.71, 3.85 (each 3H, s, 2X-OCH3), 6.81 (2H,
d, J= 8.80 Hz, H-30,50), 6.96 (2H, d, J= 8.80 Hz, H-20,60),
7.02 (2H, d, J= 8.80 Hz, H-300,500), 7.22 (2H, d, J= 8.80 Hz,
H-200,600)
160.92 (C‚O), 114.79 (CN), 55.67, 55.83 (2X-OCH3), 113.43
(C-4), 113.90 (C-30,50), 114.46 (C-300,500), 125.93 (C-10), 127.76
(C-100), 131.02 (2C), 131.22 (2C), 146.37 (C-5), 152.17 (C-6),
158.13 (C-40), 159.89 (C-400)
2d 12.62 (1H, s, NH), 0.97 (3H, t, J= 7.32 Hz, CH3), 4.13 (2H, q,
J= 7.32 Hz, CH2), 7.12 (3H, d, J= 6.60 Hz, H-3
0,40,50), 7.20
(3H, t, J= 8.08 Hz, H-300,400,500), 7.33 (4H, m, H-20,200,60,600)
163.8 (COO), 158.88 (C‚O), 13.77 (CH3), 62.11 (CH2),
128.09 (C-20,60), 128.44 (C-30,40,50), 128.80 (C-300,400,500),
129.31 (C-200,600), 133.82 (C-4), 133.91 (C-100), 134.90 (C-10),
143.28 (C-5), 147.70 (C-6)
2e 12.57 (1H, s, NH), 1.04 (3H, t, J= 6.60 Hz, CH3), 4.14 (2H, q,
J= 7.36 Hz, CH2), 6.98 (4H, t, J= 8.80 Hz, H-2
0,30,50,60),
7.36 (2H, d, J= 8.08 Hz, H-300,500), 7.44 (2H, d, J= 8.80 Hz,
H-200,600)
163.36 (COO), 158.55 (C‚O), 13.83 (CH3), 62.39 (CH2),
123.66 (C-40), 124.12 (C-400), 130.35 (C-20,60), 130.81 (C-200,600),
132.55 (C-30,50), 131.98 (C-300,500), 137.33 (C-4), 133.47 (C-100);
134.19 (C-10), 141.74 (C-5), 146.20 (C-6)
2f 12.67 (1H, s, NH), 1.02 (3H, t, J= 7.32 Hz, CH3), 3.73, 3.76
(each 3H, s, 2X-OCH3), 4.15 (2H, q, J= 7.32 Hz, CH2), 6.72
(2H, d, J= 8.80 Hz, H-30,50), 6.79 (2H, d, J= 8.76 Hz,
H-300,500), 7.03 (4H, d, J= 8.80 Hz, H-20,200,60,600)
164.17 (COO), 160.24 (C‚O), 13.91 (CH3), 55.29, 55.34 (2X-
OCH3), 62.02 (CH2), 113.53 (C-3
0,50), 113.89 (C-300,500), 126.15
(C-4), 127.55 (C-10),128.40, 130.34 (2C), 130.69 (2C), 133.65
(C-100),142.99 (C-5), 147.57 (C-6), 159.04 (C-40), 159.89 (C-400)
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dazine-4-carboxylate (2f)
White powder, m.p. 204–206 C, yield 54%; IR (cm1): 1642
(C‚O), 1740 (COO); MS: m/z 380 [M+C21H20N2O5]
(100%), 351 [M+C2H5] (2.20%), 335 [M+C2H5O]
(17.02%); NMR (dH, dC): Table 1.
2.3. General procedure for the preparation of 3-chloro-
pyridazinones (3a–e)
A mixture of the pyridazinone 2a,c–f (0.002 mol) and phos-
phoryl chloride (6 ml) was heated to 100 C on oil bath for
some hours. After cooling, excess reagent was removed under
reduced pressure and the mixture was poured into a mixture of
ice and 10% ammonia. The precipitate was ﬁltered, washed
with water and recrystallised from ethanol. NMR data of
3a–e were reported in Table 2.2.3.1. 3-Chloro-5,6-diphenyl-pyridazine-4-carbonitrile (3a)
Beige powder, reaction time 8 h, m.p. 136–138 C, lit. (Brit.
Patent, 1959) 114 C, yield 42%; IR(cm1): 2238.25 (CN);
MS: m/z 291 [M+] (C17H10N3Cl] (61.17%);
1H NMR and
13C NMR: Table 2.
2.3.2. 3-Chloro-5,6-bis(4-methoxyphenyl)-pyridazine-4-
carbonitrile (3b)
White powder, reaction time 9 h, m.p. 162–164 C, yield 57%;
IR (cm1): 2240.15 (CN); MS: m/z 351 [M+] (C19H14N3O2
35-
Cl) (100%); 1H NMR and 13C NMR: Table 2.
2.3.3. 3-Chloro-5,6-diphenyl-pyridazine-4-carboxilic acid ethyl
ester (3c)
Yellowish needles, reaction time 12 h, m.p. 132–134 C, lit.
(Brit. Patent, 1959) 134 C, yield 63%; IR (cm1): 1734.1(C‚O); MS: m/z 338 [M+] (C19H15N2O2
35Cl) (42.28%); 1H
NMR and 13C NMR: Table 2.
2.3.4. 5,6-Bis(4-bromophenyl)-3-chloro-pyridazine-4-carboxilic
acid ethyl ester (3d)
Light brown powder, reaction time 15 h, m.p. 132–134 C,
yield 65%; IR (cm1): 1731.20 (C‚O); MS: m/z 494 [M+]
(C19H13N2O2
79,79Br2
35Cl) (22.21%); 1H NMR and 13C
NMR: Table 2.
2.3.5. 3-Chloro-5,6-bis(4-methoxyphenyl)-pyridazine-4-
carboxilic acid ethyl ester (3e)
Brown needles, reaction time 8 h, m.p. 122–124 C, yield 55%;
IR (cm1): 1732.20 (C‚O); MS: m/z 398 [M+] (C21H19N2-
O4
35Cl) (100%); 1H NMR and 13C NMR: Table 2.2.4. Typical procedure for preparation of 3-aylamino-
pyridazines (4)
Compounds 4a–r were synthesized following the usual way for
nucleophilic substitution of chlorine by an organic amine. A
mixture of 3-chlorpyridazine 3 (0.002 mol) and substituted ani-
line (0.04 mol) was reﬂuxed in EtOH (30–40 ml) on an oil bath
for some hours following the reaction by TLC. After reaction
completion, the mixture evaporated to dryness and the precip-
itate washed with cold water and recrystallised from ethanol.
Physical properties as well as IR and mass spectral data are de-
picted in Table 3.
2.4.1. 5,6-Diphenyl-3-(p-tolylamino)-pyridazine-4-carbonitrile
(4a)
Yellow needles; MS: m/z 362 [M+] (C24H18N4) (76.67%);
1H
NMR(CDCl3): d 2.38 (3H, s, CH3), 7.62 (2H, d, J= 8.80 Hz,
Table 2 NMR spectral data (CDCl3) of chloro-pyridazines 3a–e.
Compound
No.
Chemical shifts (dH) in ppm Chemical shifts (dC) in ppm
3a 7.28 (2H, t, J= 5.60 Hz, H-40,400), 7.33 (2H, t, J= 5.60 Hz, H-
30,50), 7.39 (2H, t, J= 5.60 Hz, H-300,500), 7.43 (2H, t,
J= 6.00 Hz, H-20,60), 7.48 (2H, t, J= 6.00 Hz, H-200,600)
159.72 (C-3), 114.85 (CN), 112.55 (C-4), 128.38 (C-20,60), 129.12
(C-200,600), 129.24 (C-30,50), 129.79 (C-40), 129.90 (C-300,500),
130.59 (C-400), 132.21 (C-100), 134.68 (C-10), 143.73 (C-5), 154.02
(C-6)
3b 3.80, 3.85 (each 3H, s, 2X-OCH3), 6.81 (2H, d, J= 6.80 Hz, H-
30,50), 6.94 (2H, d, J= 6.80 Hz, H-300,500), 7.22 (2H, d,
J= 7.20 Hz, H-20,60), 7.29 (2H, d, J= 6.80 Hz, H-200,600)
159.42 (C-3), 114.46 (CN), 55.32, 55.41 (2X-OCH3), 113.02 (C-
4), 113.96 (C-30,50), 114.70 (C-300,500), 124.32 (C-100), 126.88 (C-
10), 130.98 (C-20,60),131.44 (C-200,600), 143.33 (C-5), 153.42 (C-6),
160.88 (C-40), 161.36 (C-400)
3c 1.06 (3H, t, J= 5.60 Hz, CH3), 4.19 (3H, q, J= 5.60 Hz, CH2),
7.16 (2H, d, J= 5.60 Hz, H-30,50), 7.27 (2H, d, J= 6.00 Hz, H-
20,60), 7.39 (6H, m, H-200,300,40,400,500,600)
163.38 (C‚O), 150.7 (C-3), 13.59 (CH3), 62.60 (CH2), 128.12
(C-20,60), 128.58 (C-200,600), 129.06 (C-30,50), 129.17 (C-40),
129.29 (C-400), 129.27 (C-300,500), 133.24 (C-4), 133.34 (C-100),
135.32 (C-10), 137.88 (C-5), 159.83 (C-6)
3d 1.13 (3H, t, J= 5.60 Hz, CH3), 4.23 (2H, q, J= 5.60 Hz, CH2),
7.04 (2H, d, J= 6.40 Hz, H-20,60), 7.24 (2H, d, J= 6.40 Hz, H-
200,600), 7.44 (2H, d, J= 6.40 Hz, H-30,50), 7.50 (2H, d,
J= 6.80 Hz, 300,500)
163.08 (C‚O), 151.1 (C-3), 13.69 (CH3), 62.90 (CH2), 124.23
(C-400), 124.31 (C-40), 130.60 (C-20,60), 131.44 (C-200,600), 131.64
(C-30,50), 131.89 (C-4), 132.16 (C-300,500), 133.20 (C-100), 133.90
(C-10), 136.49 (C-5), 158.47 (C-6)
3e 1.13 (3H, t, J= 6.00 Hz, CH3), 3.80, 3.82 (each 3H, s, 2X-
OCH3), 4.22 (3H, q, J= 6.00 Hz, CH2), 6.81 (2H, d,
J= 6.80 Hz, H-30,50), 6.86 (2H, d, J= 7.20 Hz, H-300,500), 7.09
(2H, d, J= 6.80 Hz, H-20,60), 7.30 (2H, d, J= 7.20 Hz, 200,600)
163.75 (C‚O), 150.15 (C-3), 13.76 (CH3), 55.24 (OCH3), 55.29
(OCH3), 62.54 (CH2), 113.71 (C-3
0,50), 114.21 (C-300,500), 125.62
(C-4), 127.18 (C-10), 130.49 (C-20,60), 131.43 (C-200,600), 133.13
(C-100), 137.37 (C-5), 159.59 (C-6), 160.32 (C-40), 163.73 (C-400)
Table 3 Physical properties, IR and Ms spectra of 3-arylamino-pyridazines 4a–r.
Compound No. m.p. (C) Reaction time (h) Yield (%) Molecular weight IR (cm1)
4a 210–212 27 39 C24H18N4 2222 (CN), 3345 (NH)
4b 222–223 26 50 C26H22N4O2 2227 (CN), 3331 (NH)
4c 158–160 26 32 C25H20N4 2229 (CN), 3289 (NH)
4d 194–195 28 49 C27H24N4O2 2229 (CN), 3330 (NH)
4e 218–220 26 51 C23H15N4Cl 2222 (CN), 3234 (NH)
4f 241–242 26 48 C25H19N4O2Cl 2229 (CN), 3329 (NH)
4g 288–290 27 50 C23H14N4Cl2 2231 (CN), 3295 (NH)
4h 274–275 28 35 C25H18N4O2Cl2 2230 (CN), 3240 (NH)
4i 98–100 27 56 C26H23N3O2 1734 (C‚O), 3367 (NH)
4j 191–192 31 51 C26H21N3O2Br2 1703 (C‚O), 3363 (NH)
4k 99–100 26 39 C27H25N3O2 1692 (C‚O), 3342 (NH)
4l 179–180 18 75 C27H23N3O2Br 1710 (C‚O), 3364 (NH)
4m 160–162 28 40 C29H29N3O4 1708 (C‚O), 3367 (NH)
4n 154–156 26 47 C25H20N3O2Cl 1716 (C‚O), 3401 (NH)
4o 217–218 17 52 C25H18N3O2Br2Cl 1690 (C‚O), 3313 (NH)
4p 171–172 28 67 C27H24N3O4Cl 1707 (C‚O), 3369 (NH)
4q 180–182 26 53 C25H19N3O2Cl2 1716 (C‚O), 3354 (NH)
4r 181–182 26 77 C25H17N3Br2Cl2 1703 (C‚O), 3361 (NH)
104 H.S. Alonazy et al.H-200,600), 7.42 (3H, m, NH, H-20,60), 7.25 (10H, m, others aro-
matic protons); 13C NMR(CDCl3): d 21.10 (CH3), 100.22 (C-
4), 122.78 (C-2000,6000), 128.43 (2C), 128.70 (C-40), 129.09 (2C),
129.57 (2C), 129.83 (2C), 129.87 (2C), 130.02 (C-400), 155.01




Yellow needles; MS: m/z 422 [M+] (C26H22N4O2) (63.90%);
1H NMR(CDCl3): d 2.37 (3H, s, CH3), 3.79 (6H, s, 2OCH3),
6.78 (2H, d, J= 8.76 Hz, H-30,50), 6.92 (2H, d, J= 8.76 Hz,
H-300,500), 7.25 (7H, m, others aromatic protons), 7.61 (2H, d,
J= 8.80 Hz, H-200,600); 13C NMR(CDCl3): d 21.04 (CH3),
55.32, 55.44 (2X-OCH3), 113.73 (C-3
0,50), 114.54 (2C), 114.01
(C-4), 121.84 (C-6000), 129.86 (3C), 130.97 (C-20,60), 131.01(2C), 134.94 (C-10,100), 145.50 (C-5), 152.73 (C-1000), 153.49
(C-6), 160.42 (C-40,400), 161.15 (C-3).
2.4.3. 3-(Ethylphenylamino)-5,6-diphenylpyridazine-4-
carbonitrile (4c)
Orange needles; MS: m/z 376 [M+] (C25H20N4) (37.08%);
1H
NMR(CDCl3): d 1.26 (3H, t, J= 7.30 Hz, CH2CH3), 2.70
(2H, q, J= 7.30 Hz, CH2CH3), 7.03 (1H, d, J= 7.32 Hz, H-
30), 7.27 (7H, m, others aromatic protons), 7.32 (2H, t,
J= 7.32 Hz, H-40,400), 7.42 (3H, m, NH, H-20,60), 7.56 (1H,
s, NH), 7.60 (1H, d, J= 8.08 Hz, H-200); 13C NMR(CDCl3):
d 15.64 (CH3), 28.97 (CH2), 100.37 (C-4), 118.89 (C-6000),
120.96 (C-2000), 124.64 (C-4000), 128.21 (C-20,60), 128.81 (C-5000),
129.02 (2C), 129.36 (2C), 129.64 (2C), 130.24 (C-400), 133.45
(C-3000), 135.37 (C-1000), 137.58 (C-10,100), 143.64 (C-3), 145.70
(C-40), 153.10 (C-6), 153.67 (C-5).
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pyridazine-4-carbonitrile (4d)
Light brown powder; MS: m/z 436 [M+] (C27H24N4O2)
(60.20%); 1H NMR(CDCl3): d 1.26 (3H, t, J= 7.36 Hz,
CH2CH3), 2.69 (2H, q, J= 8.08 Hz, CH2CH3), 3.79 (6H, s,
2OCH3), 6.78 (2H, d, J= 8.80 Hz, H-3
0,50), 6.91 (2H, d,
J= 8.80 Hz, H-300,500), 7.01 (1H, d, J= 7.36 Hz, H-4000), 7.26
(4H, m, H-200,600,2000,6000), 7.31 (2H, t, J= 8.08 Hz, H-20,60),
7.57 (1H, s, NH), 7.61 (1H, d, J= 8.08 Hz, H-6000); 13C
NMR(CDCl3): d 15.64 (CH3), 28.98 (CH2), 55.31, 55.43 (2X-
OCH3), 100.11 (C-4), 113.72 (C-3
0,50), 114.35 (CN), 114.52
(C-300,500), 120.64 (C-2000), 118.59 (C-6000), 124.27, 125.65 (C-10,
C-4000), 128.02 (C-100), 129.19 (C-5000), 130.95 (2C), 131.00
(2C), 137.90 (C-5), 145.64 (C-1000,3000), 153.00, 153.55 (C-3,C-
6), 160.02, 161.04 (40,400).
2.4.5. 3-(4-Chlorophenylamino)-5,6-diphenylpyridazine-4-
carbonitrile (4e)
Yellowish needles; MS: m/z 382 [M+] (C23H15N4
35Cl)
(63.05%); 1H NMR (DMSO-d6): d 7.28 (5H, m, H-200,300,400,
500,600), 7.33-7.44 (7H, other aromatic protons), 7.74 (2H, d,
J= 8.80 Hz, H-3000,5000), 9.57 (1H, s, NH).; 13C NMR (DMSO-d6):
d 101.04 (C-4), 123.88 (C-2000,6000), 127.68 (C-4000), 128.45 (2C),
128.83 (C-40), 128.99 (2C), 129.11 (2C), 129.82 (2C), 129.90
(2C), 130.08 (C-400), 134.38 (C-10), 136.59 (C-100), 138.91 (C-5),
143.71 (C-1000), 153.74 (C-6), 154.69 (C-3).
2.4.6. 3-(4-Chlorophenylamino)-5,6-bis(4-methoxyphenyl)-
pyridazine-4-carbonitrile (4f)
Yellowish needles; MS: m/z 442 [M+] (C25H19N4O2
35Cl)
(82.34%); 1H NMR(CDCl3): d 3.84 (6H, s, 2OCH3), 6.79
(2H, dd, J= 5.12 Hz, H-30,50), 6.92 (2H, dd, J= 8.80 Hz,
H-300,500), 7.25 (4H, m, H-2000,6000,3000,5000), 7.35 (3H, dd, J=
8.80 Hz, H-20,60, NH), 7.71 (2H, dd, J= 8.08 Hz, H-200,600);
13C NMR(CDCl3): d 55.34, 55.46 (OCH3), 112.50 (C-4),
113.79 (2C), 114.60 (2C), 115.00 (C-4000), 117.50 (C-10), 122.56
(C-2000,6000), 125.34 (C-100), 127.43 (C-5), 129.31 (2C), 130.00
(C-1000), 130.97 (2C), 131.07 (C-3000,5000), 153.35(C-6),
153.37(C-3), 160.25 (C-40), 161.22 (C-400).
2.4.7. 3-(3,4-Dichlorophenylamino)-5,6-diphenylpyridazine-4-
carbonitrile (4g)
Yellowish powder; MS: m/z 416 [M+] (C23H14N4
35Cl2)
(45.23%); 1H NMR (DMSO-d6): d 7.28 (5H, m, H-
2000,40,400,5000,6000), 7.33 (2H, d, J= 7.32 Hz, H-30,50), 7.42 (3H,
d, J= 5.12 Hz, H-300,500,60), 7.62 (1H, d, J= 8.80 Hz, H-20),
7.73 (1H, dd, J= 8.80 Hz, H-600), 8.08 (1H, d, J= 2.20 Hz,
H-200), 9.72 (1H, s, NH); 13C NMR (DMSO-d6): d 101.69
(C-4), 121.97 (C-6000), 123.11 (C-2000), 125.17 (C-4000), 128.48
(C-20,60), 128.94 (C-40), 129.13 (C-200,600), 129.81 (C-30,50),
129.94 (C-300,500), 130.14 (C-400), 130.94 (C-5000), 131.30 (C-3000),
134.28 (C-10), 136.47 (C-100), 140.26 (C-5), 143.89 (C-1000),
154.23 (C-6), 154.43 (C-3).
2.4.8. 3-(3,4-Dichlorophenylamino)-5,6-bis(4-
methoxyphenyl)pyridazine-4-carbonitrile (4h)
Greenish needles; MS: m/z 476 [M+] (C25H18N4O2
35Cl2)
(100%); 1H NMR (DMSO-d6): d 3.35 (6H, s, 2X-OCH3),
6.85 (2H, d, J= 8.04 Hz, H-30,50), 7.01 (2H, d, J= 8.08 Hz,
H-300,500), 7.20 (2H, d, J= 8.80 Hz, H-20,60), 7.27 (2H, d,
J= 8.80 Hz, H-200,600), 7.61 (1H, d, J= 8.80 Hz, H-6000), 7.84(1H, d, J= 8.80 Hz, H-5000), 8.07 (1H, s, J= 8.80 Hz, H-2000),
9.63 (1H, s, NH).
2.4.9. 5,6-Diphenyl-3-(p-tolylamino)-pyridazine-4-carboxylic
acid ethyl ester (4i)
Greenish needles; MS: m/z 409 [M+] (C26H23N3O2) (53.81%);
1H NMR(CDCl3): d 0.70 (3H, t, J= 6.60 Hz, CH2CH3), 2.34
(3H, s, CH3), 4.17 (2H, q, J= 8.04 Hz, CH2CH3), 7.37 (14H,
m, NH, other hydrogen), 7.54 (1H, d, J= 8.04 Hz, H-200). 13C
NMR(CDCl3): d 13.14 (–CH2CH3), 21.01 (CH3), 62.74
(–CH2CH3), 163.52 (CO).
2.4.10. 5,6-Bis(4-bromophenyl)-3-(p-tolylamino)-4-carboxylic
acid ethyl ester (4j)
Greenish needles; MS: m/z 565 (C26H21N3O2Br2);
1H
NMR(CDCl3): d 0.80 (3H, t, J= 7.24 Hz, CH2CH3), 2.34
(3H, s, CH3), 4.01 (2H, q, J= 7.36 Hz, CH2CH3), 6.94 (2H,
d, J= 8.04 Hz, H-2000,6000), 7.11 (2H, d, J= 8.08 Hz, H-
3000,5000), 7.17 (2H, d, J= 8.80 Hz, H-20,60), 7.35 (2H, d,
J= 8.80 Hz, H-200,600), 7.46 (2H, d, J= 8.04 Hz, H-30,50),
7.64 (2H, d, J= 8.80 Hz, H-300,500), 8.34 (1H, s, NH). 13C
NMR(CDCl3): d 13.42 (–CH2CH3), 20.96 (CH3), 62.41
(–CH2CH3), 114.57 (C-4
0), 121.05 (C-2000,6000), 129.58 (C-20,60),
130.64 (C-200,600), 131.23 (C-3000,5000), 131.34 (C-30,50), 131.74
(C-300,500), 122.68 (C-40), 122.90 (C-400), 133.28 (C-4000), 135.34
(C-10), 135.47 (C-100), 136.30 (C-5), 137.47 (C-1000), 152.45
(C-6), 152.86 (C-3), 166.1 (CO).
2.4.11. 3-(Ethylphenylamino)-5,6-diphenylpyridazine-4-
carboxylic acid ethyl ester (4k)
Greenish needles; MS: m/z 423 [M+] (C27H25N3O2) (50.40%);
1H NMR(CDCl3): d 0.71 (3H, t, J= 6.60 Hz, C-CH2CH3),
1.26 (3H, t, J= 8.08 Hz, O-CH2CH3), 2.68 (2H, q, J=
8.08 Hz, C-CH2CH3), 3.95 (2H, q, J= 7.32 Hz, O-CH2CH3),
6.93 (1H, d, J= 7.32 Hz, H-6000), 7.07 (2H, d, J= 7.32 Hz,
H-30,50), 7.30 (10H, m, other hydrogen), 7.62 (1H, s, H-2000),
7.66 (1H, d, J= 9.56 Hz, H-5000). 13C NMR(CDCl3): d 13.16
(O-CH2CH3), 15.79 (C-CH2CH3), 29.07 (C-CH2CH3), 62.18
(O-CH2CH3), 113.50 (C-4), 117.99 (C-6
000), 119.99 (C-2000),
122.84 (C-4000), 127.83 (2C), 127.94 (C-5000), 128.31 (2C), 128.40
(C-40), 128.96 (C-400), 129.09 (2C), 129.83 (2C), 136.54 (C-10),
136.60 (C-100), 138.80 (C-3000), 139.22 (C-5), 145.33 (C-6),
153.00 (C-1000), 154.19 (C-3), 167.36 (CO).
2.4.12. 5,6-Bis(4-bromophenyl)-3-(ethylphenylamino)-
pyridazine-4-carboxylic acid ethyl ester (4l)
Yellowish needles; MS: m/z 409 [M+] (C27H23N3O2
79,79Br2)
(100%); 1H NMR(CDCl3): d 0.81 (3H, t, J= 6.60 Hz,
C-CH2CH3), 1.25 (3H, t, J= 8.08 Hz, O-CH2CH3), 2.67
(2H, q, J= 7.36 Hz, C-CH2CH3), 3.96 (2H, q, J= 6.60 Hz,
O-CH2CH3), 6.97 (2H, d, J= 4.40 Hz, H-2
0,60), 7.12 (2H, d,
J= 8.80 Hz, H-200,600), 7.31 (7H, m, H-4000,6000), 7.37 (2H, d,
J= 6.60 Hz, H-30,50), 7.46 (2H, d, J= 6.60 Hz, H-300,500),
7.54 (1H, s, H-2000), 7.60 (1H, d, J= 8.08 Hz, H-5000), 8.61
(1H, s, NH). 13C NMR(CDCl3): d 13.25 (O-CH2CH3), 15.70
(C-CH2CH3), 29.01 (C-CH2CH3), 62.49 (O-CH2CH3), 115.60
(C-4), 118.63 (C-6000), 120.65 (C-2000), 122.90 (C-40), 123.08
(C-400), 123.60 (C-4000), 129.04 (C-5000), 130.62 (2C), 131.32
(C-200,30,50,600), 131.78 (2C), 134.97 (C-10), 135.54 (C-100),
138.05 (C-5), 138.54 (C-3000), 145.44 (C-6), 152.52 (C-1000),
152.19 (C-1000), 166.48 (CO).
106 H.S. Alonazy et al.2.4.13. 3-(Ethylphenylamino)-5,6-bis(4-methoxyphenyl)-
pyridazine-4-carboxylic acid ethyl ester (4m)
Yellowish powder; MS: m/z 483 [M+C29H29N3O4)
(54.52%); 1H NMR(CDCl3): d 0.80 (3H, t, J= 7.32 Hz,
C-CH2CH3), 1.24 (3H, t, J= 7.36 Hz, O-CH2CH3), 2.65
(2H, q, J= 7.32 Hz, C-CH2CH3), 3.81, 3.78 (each 3H, s,
2X-OCH3), 3.92 (2H, q, J= 6.60 Hz, O-CH2CH3), 6.75
(2H, d, J= 9.56 Hz, H-30,50), 6.82 (2H, d, J= 8.80 Hz, H-
300,500), 6.94 (1H, d, J= 6.60 Hz, H-6000), 6.98 (2H, d,
J= 8.80 Hz, H-20,60), 7.20 (2H, d, J= 8.80 Hz, H-200,600),
7.28 (1H, s, J= 8.08 Hz, H-4000), 7.53 (1H, s, H-2000), 7.58
(1H, d, J= 7.36 Hz, H-5000), 8.40 (1H, s, NH). 13C
NMR(CDCl3): d 13.42 and 62.19 (O-CH2CH3), 15.70 and
29.00 (C-CH2CH3), 55.27, 55.41 (2X-OCH3), 113.43 (2C),
113.70 (C-4), 113.90 (2C), 118.37 (C-6000), 118.46 (C-2000),
120.49 (C-4000), 123.25 (C-5000), 128.25 (C-10), 128.75 (C-100),
130.45 (2C), 130.59 (C-5), 131.11 (2C), 138.81 (C-3000),
145.36 (C-6), 152.12 (C-1000), 153.88 (C-3), 159.59 and 159.94
(C-40, C-400), 166.87 (CO).
2.4.14. 3-(4-Chlorophenylamino)-5,6-diphenylpyridazine-4-
carboxylic acid ethyl ester (4n)
Yellowish powder; MS: m/z 429 [M+] (C25H20N3O2
35Cl]
(62.32%); 1H NMR(CDCl3): d 0.67 (3H, t, J= 7.32 Hz,
–CH2CH3), 3.91 (2H, q, J= 7.32 Hz, –CH2CH3), 7.02 (2H,
d, J= 6.60 Hz, H-2000,6000), 7.29 (10H, m, other hydrogen),
7.72 (2H, d, J= 6.60 Hz, H-200,600), 8.52 (1H, s, NH); 13C
NMR(CDCl3): d 13.11, 62.34 (O-CH2CH3), 116.10 (C-4),
122.04 (C-2000,6000), 127.88 (2C), 128.34 (2C), 128.10 (C-40),
128.40 (C-4000), 128.34 (2C), 128.53 (C-400), 128.90 (2C),
129.01 (2C), 129.79 (2C), 136.12 (C-100), 136.23 (C-100),
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Scheme2.4.15. 5,6-Bis(4-bromophenyl)-3-(4-chlorophenylamino)-
pyridazine-4-carboxylic acid ethyl ester (4o)





methoxyphenyl)pyridazine-4-carboxylic acid ethyl ester (4p)
Yellowish powder; MS: m/z 489 [M+] (C27H24N3O4
35Cl)
(68.53%); 1H NMR(CDCl3): d 0.78 (3H, t, J= 7.36 Hz,
O-CH2CH3), 3.79, 3.75 (each 3H, s, 2X-OCH3), 3.98 (2H, q,
J= 8.08 Hz, O-CH2CH3), 6.73 (2H, d, J= 8.80 Hz,
H-2000,6000), 6.81 (2H, d, J= 8.80 Hz, H-30,50), 6.97 (2H, d,
J= 8.04 Hz, H-300,500), 7.19 (2H, d, J= 8.04 Hz, H-3000,5000),
7.28 (2H, d, J= 8.80 Hz, H-20,60), 7.73 (2H, d, J= 8.76 Hz,
H-200,600), 8.23 (1H, s, NH); 13C NMR(CDCl3): d 13.40, 62.28
(O-CH2CH3), 55.24, 55.41 (2X-OCH3), 113.40 and 113.92
(C-30,50,300,500), 116.44 (C-4000), 121.67 (C-2000,6000), 127.76 (C-10),
128.50 (C-100), 128.90 (C-20,60), 130.42 (2C), 131.10 (2C),
137.98 (C-5), 138.67 (C-1000), 152.02 (C-6), 154.49 (C-3),
159.54, 159.92 (C-40,C-400), 167.37 (CO).
2.4.17. 3-(3,4-Dichlorophenylamino)-5,6-diphenylpyridazine-4-
carboxylic acid ethyl ester (4q)
Yellow needles; MS: m/z 463 [M+] (C25H19N3O2
35,35Cl)
(66.66%); 1H NMR(CDCl3): d 0.68 (3H, t, J= 6.60 Hz,
O-CH2CH3), 3.90 (2H, q, J= 6.63 Hz, O-CH2CH3), 7.02
(2H, d, J= 7.40 Hz, H-30,50), 7.29 (m, other hydrogen), 7.35
(1H, d, J= 8.80 Hz, H-2000), 7.60 (1H, dd, J= 8.80 Hz, H-
6000), 8.02 (1H, d, J= 2.20 Hz, H-5000), 8.63 (1H, s, NH); 13C
NMR(CDCl3): d 13.08, 62.48 (CH2CH3), 116.24 (C-4),
120.02 (C-6000), 122.11 (C-2000), 126.27 (C-4000), 127.93 (2C),



































































Novel 5,6-bis-(4-substitutedphenyl)-2H(3)-pyridazinones: Synthesis and reactions 107(C-40,400), 132.69 (C-3000), 135.97, 136.02 (C-10,C-100), 138.57 (C-
5), 139.82 (C-1000), 152.16 (C-6), 154.95 (C-3), 166.85 (CO).
2.4.18. 3-(3,4-Dichlorophenylamino)-5,6-bis(4-
bromophenyl)pyridazine-4-carboxylic acid ethyl ester (4r)
Yellow needles; MS: m/z 487 (C25H17N3Br2Cl2);
1H NMR-
(CDCl3): d 0.78 (3H, t, J= 7.36 Hz, CH2CH3), 3.98 (2H, q,
J= 7.32 Hz, CH2CH3), 6.93 (2H, d, J= 8.04 Hz, H-2
0,60),
7.09 (2H, d, J= 8.80 Hz, H-200,600), 7.37 (3H, t, J= 8.08 Hz,
H-30,50,2000), 7.46 (2H, d, J= 8.80 Hz, H-300,500), 7.60 (1H, dd,
J= 8.76 Hz, H-6000), 8.02 (1H, d, J= 2.20 Hz, H-5000), 8.67
(1H, s, NH); 13C NMR(CDCl3): d 13.19,62.75(O-CH2CH3),
115.18 (C-4), 120.06 (C-6000), 122.17 (C-2000), 123.11 (C-40),
123.18 (C-400), 126.48 (C-4000), 130.47 (C-5000), 130.56 (C-20,60),
131.32 (C-200,600), 131.36 (2C), 131.82 (2C), 132.75 (C-3000),
134.87 (C-10), 134.94 (C-100), 138.21, 138.41 (C-1000,C-5),
152.37 (C-6), 153.52 (C-3), 166.61 (CO).
3. Results and discussion
The route for the synthesis of pyridazinones 2a–f, and
3-chloro-pyridazine 3a–e starting from 1a–c, is illustrated in
Scheme 1. Initially, we planned to prepare 5,6-(4-substituted-
phenyl)-3-(2H)-pyridazinones (2a–f) by using Microwave tech-
nique but unfortunately this method led to poor yields of the
required pyridazinones. Further more, attempts for obtaining
3a–e following the latter technique gave mixture of com-
pounds. However, compounds 2a–f and 3a–f were obtained
in good-moderate yields (see experimental) when the conven-
tional method was used. Therefore, the cyclization of 1a–c in
the presence of sodium hydroxide, through the reaction with
ethyl cyanoacetate or diethyl malonate following the latter
method afforded the corresponding pyridazinones 2a–f, which
in turn transformed smoothly to 3a–e. Structures of all syn-
thesised compounds in Scheme 1 were conﬁrmed on the basis
of 1H,13C NMR and MS. IR spectra of monohydrazones
1a–c showed the expected signals of carbonyl and amine
groups. 1H,13C NMR data were consistent with their struc-
tures. The structure of 2a–f were conﬁrmed on the basis of
their spectroscopic analyses. Their IR spectra showed bands
in the range 1660–1700 cm1 (C‚O in pyridazine ring) in
addition to the absorption bands at around 2228 cm1
(C‚N) in 2a–c and at about 1725 cm1 (carbonyl esters) in
2d–f. Additionally, these spectra showed the stretching bands
of CH and C‚C bonds in the aromatic substituents. Full anal-
ysis of NMR data of 2a–f reported in Table 2, conﬁrmed their
structures. The assignments of all carbons in 2a–f are basically
made by comparison to 13C NMR spectra of structurally re-



















Figure 1 13C NMR assignments of 2e.ground (Hesse et al., 1997; Lambert and Mazzola, 2004),
and the aid of the off resonance, DEPT and HETCOR
NMR experiments (Fig. 1).
Reaction of 2a–f with phosphoryl chloride furnished the
corresponding chloro-pyridazine 3a–e (Scheme 1) after work-
ing up in the usual way. The structures of these compounds
were assigned on the basis of their various spectral data. IR
spectra revealed the disappearance of the carbonyl band in
the similar spectra of pyridazinones 2a–f, while the NMR data
of 3a–e ﬁrmly assigned their structures. These data were col-
lected in Table 2. Furthermore, the mass spectra showed the
expected molecular ions for these compounds(see experimen-
tal). We have included the 13C NMR spectral data of the
known compounds 2a,d (Schemidt and Druey, 1954; Druey
and Schemidt, 1957; Brit. Patent, 1959; Shalaby, 1990) and
3a (Deep et al., 1991) in the experimental for the ﬁrst time as
it seemed for us from literature survey.
Heating of 3a–e with various substituted anilines led to the
formation of a series of corresponding 3-arylaminopyridazines
4a–r in moderate yields. This reaction is outlined in Scheme 2.
Characterization of 4a–r was based mainly on the spectro-
scopic means and in particular their NMR data which are de-
picted in Table 3. The assignments of the resonances in the
NMR spectra was based on chemical shifts theory (Hesse
et al., 1997; Lambert and Mazzola, 2004), signal intensity
arguments and multiplicities, and in part by comparison to
13C NMR spectra of structurally related compounds (Matsuda
et al., 2001).
4. Conclusion
In the present work, it is reported the synthesis of novel 5,6-
bis(4-substitutedphenyl)-2H(3)-pyridazinones 2b,c,e,f. Reaction
108 H.S. Alonazy et al.of these pyridazones with phosphoryl chloride led to the for-
mation of the new 3b–e. Furthermore, a series of the previ-
ously unknown 4a–r have been synthesized in appreciable
yields from the reaction of 3a–e with various arylamines.References
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